Pharmaceutical pollution in the Baltic Sea poses a critical threat to marine ecosystems, prompting researchers across Sweden, Finland, Lithuania, and Latvia to push for changes in how medicines are prescribed and managed throughout their life cycle. Surrounded by nine countries in northeastern Europe, the semi-enclosed inland sea is among the most polluted marine environments globally, carrying a legacy of post-Second World War munitions alongside modern industrial chemicals, microplastics, and agricultural runoff.
Life-Cycle Management of Pharmaceuticals in the Baltic Region
Researchers from four countries argue that addressing wastewater treatment alone cannot solve the Baltic Sea’s pharmaceutical burden. Marmar Nekoro, a researcher at the faculty of pharmacy at Uppsala University in Sweden, states that solutions must span the entire life cycle of a medication, from initial prescription decisions to patient usage and the return of unused drugs to pharmacies. According to Kristina Garuolienė, a researcher at Vilnius University, rational prescribing practices require doctors to weigh environmental hazards when choosing between alternative medications.
Active pharmaceutical ingredients enter the Baltic Sea through multiple channels, including household and hospital wastewater, agricultural runoff, companion animal waste, and industrial discharges. A decade-old report by UNESCO and the Baltic Marine Environment Protection Commission estimated that wastewater treatment plants release approximately 1,800 tonnes of pharmaceuticals into the sea annually. Most regional treatment facilities still lack a fourth treatment stage designed specifically to remove pharmaceutical residues. Because human bodies do not absorb entire dosages, large portions of ingested drugs are excreted. Once discharged, these compounds break down very slowly. For example, carbamazepine—a prescription medication used for epilepsy, nerve pain, and bipolar disorder—takes nearly three and a half years to reduce by half, leading to steady accumulation.
Ecological Impacts on Marine Wildlife
While researchers emphasize that swimming in the Baltic Sea does not pose direct chemical harm to humans beyond antimicrobial resistance risks, the accumulation of pharmaceuticals profoundly disrupts aquatic life. Synthetic oestrogens cause feminisation in fish and frog populations, threatening species survival. Additionally, exposure to common painkillers reduces the energy available for metabolism and growth in the Baltic blue mussel (Mytilus edulis), a key species in the ecosystem responsible for water filtration. Disruptions to mussel populations increase stress on an ecosystem already vulnerable to widespread eutrophication and industrial contamination.
Pharmaceutical pollution sources and proposed reduction strategies in the Baltic Sea
How do pharmaceuticals enter the Baltic Sea?
Drugs enter the sea via household and hospital wastewater, agricultural runoff, companion animal waste, and industrial discharge. Wastewater treatment plants release an estimated 1,800 tonnes of pharmaceuticals into the basin each year.
What are researchers proposing to reduce this pollution?
Researchers from Sweden, Finland, Lithuania, and Latvia advocate for rational prescribing, where doctors consider environmental impacts when selecting medications, alongside better disposal habits for unused drugs.
Which specific drugs are scientists monitoring?
Researchers are closely tracking substances like diclofenac, an anti-inflammatory painkiller, and carbamazepine, an epilepsy and nerve pain medication known to persist in aquatic environments for years.
Worth a look